Ok, had more beer, talked the cockatoos down and also a peacock that sounds like a child screaming, damn peacock
So a similar partnering that was hailed as a huge success by the market was when Alchemia partnered with Dr Reddys who also did all the manufacturing and they had a 50/50 split, analysts and the market alike loved the deal for this generic Fondaparinux (I was a holder from 10c and saw the 80c area).
This deal was for the US only and they had the same sort of arrangement for Europe and ROW (rest of world), though it was more a percentage than an even 50/50. The unfortunate thing for Alchemia was that it was a generic drug (again the deal was a massive win for this small biotech) and once they gained FDA approval the Branded drug maker Glaxo Smith Kline simply bought out an authorised generic and thwarted the earnings plans as they too discounted their own drug.
THIS WILL NOT HAPPEN HERE
So I guess what I'm saying is that this deal should be looked at favourably and that we should look at the fact that we could see licensing in places like Europe and the US and many other countries coming to a store near you soon
This is big, this is a company maker, this paves the way to commercialisation with a large backer who obviously likes the science. Yes there's a way to go but not many get this type of deal this early on in the piece unless great value is seen.
Have a good New Years all......
